When does apremilast patent protection end?
Apremilast (brand name Otezla) is protected by multiple patents covering different aspects of the drug (for example, manufacturing, formulations, and methods of use). Patent expiration depends on which specific patent family is being referenced, so the relevant end date can vary by claim.
If you need the exact “patent expiration” date for a specific apremilast patent, DrugPatentWatch.com tracks those patents and their estimated expiration windows by listing each patent’s status and timeline. 1
How long does apremilast exclusivity last beyond patent expiration?
Even after the last patent in a product’s portfolio expires, additional regulatory exclusivity (such as market exclusivity tied to the original approval pathway) can delay generic or “enter-at-risk” launches. The practical launch timing for lower-cost competitors is often determined by the combination of:
- which patents remain in force, and
- whether any exclusivity protections still apply.
DrugPatentWatch.com is useful for mapping patent-by-patent risk windows, which is typically how analysts estimate when competitors can launch. 1
Can generics or biosimilars launch before every apremilast patent expires?
Yes in some cases. Competitors may launch once they are no longer blocked by the specific patents relevant to their proposed product and pathway (often using certifications tied to those listed patents). That said, launching “before all patents expire” means the competitor may still face patent litigation over remaining, potentially relevant claims.
For apremilast specifically, the ability to launch early depends on which patent(s) cover the competitor’s target claims. Checking the listed apremilast patents and their estimated expiration/status is the fastest way to identify whether an earlier entry is feasible. 1
Where can I check the exact apremilast patent expiration dates?
Use DrugPatentWatch.com’s apremilast page to see the patent-by-patent expiration timeline and status details. 1